Chronomodulated drug delivery systems for the treatment of hypertension: An overview

Abstract

This review paper aims to provide an overview of chronomodulated drug delivery systems for the treatment of hypertension. Hypertension is a chronic medical condition that affects millions of people worldwide, and effective treatment is crucial to prevent complications such as heart disease and stroke. Chronomodulated drug delivery utilises the concept of circadian rhythms to optimise drug efficacy and minimise side effects. The paper examines various chronomodulated drug delivery approaches, including pulsatile, delayed-release, and chronopharmaceutical systems, highlighting their advantages and limitations. Furthermore, the potential future developments in this field are discussed, emphasising the importance of personalised medicine and the integration of wearable technology for real-time monitoring and drug administration. Overall, this review provides valuable insights into the potential of chronomodulated drug delivery systems for improving patient outcomes and minimising side effects. By utilising chronomodulated drug delivery approaches, healthcare professionals can ensure that medications are released at specific times when they are most effective, thereby maximising their therapeutic benefits. Pulsatile drug delivery systems, for example, can mimic the body’s natural circadian rhythm, allowing for targeted drug release during periods of peak efficacy. Delayed-release systems, on the other hand, can help reduce side effects by delivering drugs to specific regions of the gastrointestinal tract where they are better tolerated.

Keywords

Medications / Therapeutic benefits / Pulsatile drug delivery systems / Circadian rhythm / Gastrointestinal tract

References

[1] Aldawsari HM, Naveen NR, Alhakamy NA, et al. Compression-coated pulsatile chronomodulated therapeutic system: QbD assisted optimization. Drug Deliv. 2022;29:2258–2268.

[2] Kamel E-R, Al-Bader S. Bilateral adrenal hyperplasia;a common cause of drugrefractory hypertension yet amenable to medical treatment. J Drug Deliv Therapeut. 2020;10:79–82.

[3] Padmakumar S, Amiji MM. Long-acting therapeutic delivery systems for the treatment of gliomas. Adv Drug Deliv Rev. 2023;197:114853.

[4] Pola Kk, Kumar Rada S. An overview on ultra deformable vesicular drug delivery systems in transdermal drug delivery. Int J Appl Pharm. 2023:28–34.

[5] Hadji H, Bouchemal K. Advances in the treatment of inflammatory bowel disease: focus on polysaccharide nanoparticulate drug delivery systems. Adv Drug Deliv Rev. 2022;181:114101.

[6] Bhalerao A, Chaudhari PP. Formulation of solid lipid nanoparticles of cilnidipine for the treatment of hypertension. J Drug Deliv Therapeut. 2019;9:212–221.

[7] Alam T, Khan S, Gaba B, Haider MdF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv. 2017;24:358–369.

[8] Kumar M, Kaushik D. An overview on various approaches and recent patents on gastroretentive drug delivery systems. Recent Pat Drug Deliv Formulation. 2018;12:84–92.

[9] Zhang X, Liang T, Ma Q. Layer-by-Layer assembled nano-drug delivery systems for cancer treatment. Drug Deliv. 2021;28:655–669.

[10] Chinthaginjala H, Ahad HA, Pradeepkumar B. Chronomodulated mucoadhesive gastroretentive drug delivery system of famotidine. Adv Pharmacol Pharm. 2022;10:209–217.

[11] Kumar P, Mishra B. An overview of recent patents on oral osmotic drug delivery systems. Recent Pat Drug Deliv Formulation. 2007;1:236–255.

[12] Mignani S, El Kazzouli S, Bousmina M, Majoral J-P. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev. 2013;65:1316–1330.

[13] Singh N, Singh M, Panwar S. An overview of novel drug delivery systems for acne. Inter J Res Dev Pharm Life Sci. 2019;8:1–12.

[14] Chhetri P, Chakraborty P, Das D, Afnan T. In-situ forming polymeric drug delivery systems for ophthalmic use: an overview. J Drug Deliv Therapeut. 2021;11:98–103.

[15] Bichewar S, Pillai S, Mandloi RS, Birla N, Jain S. Formulation and evaluation of chronomodulated drug delivery system of doxofylline for treatment of nocturnal asthma. Res J Pharm Technol. 2020;13:6170–6175.

[16] Labib G. Overview on zein protein: a promising pharmaceutical excipient in drug delivery systems and tissue engineering. Expet Opin Drug Deliv. 2017;15:65–75.

[17] Ali J, Qureshi J, Amir M, Ahuja A, Baboota S. Chronomodulated drug delivery system of salbutamol sulphate for the treatment of nocturnal asthma. Indian J Pharmaceut Sci. 2008;70:351.

[18] Alekya T, Narendar D, Mahipal D, Arjun N, Nagaraj B. Design and evaluation of chronomodulated drug delivery of tramadol hydrochloride. Drug Res. 2017;68:174–180.

[19] Vadlapatla R, Wong EY, Gayakwad SG. Electronic drug delivery systems: an overview. J Drug Deliv Sci Technol. 2017;41:359–366.

[20] Asiniparthi M. Formulation and evaluation of chronomodulated drug delivery of montelukast sodium. Global J Pharm Pharmaceut Sci. 2016;1.

[21] Prisant LM, Elliott WJ. Drug delivery systems for treatment of systemic hypertension. Clin Pharm. 2003;42:931–940.

[22] Chenna R, Reddy YP. Formulation and in vivo evaluation of chronomodulated drug delivery of nimodipine. Int J Pharmaceut Sci Drug Res. 2019;11.

[23] Agarwal V, Bansal M. Chronomodulated delivery system: a tailored cap to fit different heads. Recent Pat Drug Deliv Formulation. 2012;6:171–180.

[24] Hashida M. Role of pharmacokinetic consideration for the development of drug delivery systems: a historical overview. Adv Drug Deliv Rev. 2020;157:71–82.

[25] Sowmya C, Lavakumar V, Venkateshan N, et al. Microcapsule-based chronomodulated drug delivery systems of montelukast sodium in the treatment of nocturnal asthma. Inter J Pharm Invest. 2018;8:24.

[26] Kumar P, Mishra B. Colon targeted drug delivery systems -an overview. Curr Drug Deliv. 2008;5:186–198.

[27] Patil SS, Gupta VRM. Design and in vitro evaluation of multiparticulate system for the chronomodulated delivery of lornoxicam. J Drug Deliv Therapeut. 2015;5.

[28] Patil SS, Gupta VRM. Design, in vitro and in vivo evaluation of chronomodulated delivery systems of terbutaline sulphate for nocturnal asthama. J Drug Deliv Therapeut. 2016;6.

[29] Beg S, Swain S, Gahoi S, Kohli K. Design, development and evaluation of chronomodulated drug delivery systems of amoxicillin trihydrate with enhanced antimicrobial activity. Curr Drug Deliv. 2013;10:174–187.

[30] Chaudhary S, Parejiya P, Patel H, Shelat P. Chronomodulated drug delivery system of urapidil for the treatment of hypertension. Inter J Pharm Invest. 2015;5:107.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.